CASE REPORT: SPECIFIC ABL-INHIBITOR IMATINIB IS AN EFFECTIVE TARGETED AGENT AS THE FIRST LINE THERAPY TO TREAT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A CRYPTIC NUP214::ABL1 GENE FUSION

Account has been disabled due to a violation of Terms of Service. Contact Moderators

Account has been disabled due to a violation of Terms of Service. Contact Moderators

Blog Article

Report this page